Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 509, Issue 1-2, Pages 95-106Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2016.05.015
Keywords
Nanomaterials; Nanoparticles; Regulations; EMA; ANVISA; EFSA; OECD; Rules; Law
Categories
Funding
- LOEWE initiative of the State of Hessen
Ask authors/readers for more resources
In recent years, nanotechnology has become increasingly important for global industries. Today, many nanomaterials are used as ingredients in cosmetics, food products, medical devices and pharmaceuticals. In some cases they exert unexpected risks and potentially pose a threat to human health and the environment. Regulatory authorities all over the world carefully observe recent developments in this area, striving to find a balance between consumer safety and the interests of the industry. In the following, the current legislation in the United States of America, the European Union, Asia and Brazil will be presented. Further, the requirements defined by these different authorities and methodology to investigate relevant characteristics of nanomaterials will be discussed. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available